PROAIR HFA Rx
Generic Name and Formulations:
Albuterol sulfate 90mcg/inh; metered-dose aerosol with a dose counter; CFC-free.
Indications for PROAIR HFA:
Adults and Children:
<4yrs: not established. ≥4yrs: 2 inh every 4–6hrs; in some patients: 1 inh every 4hrs may suffice. Exercise-induced bronchospasm: 2 inh 15–30 mins before exercise.
Avoid excessive use. Sensitivity to sympathomimetics. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disorders (eg, coronary insufficiency, arrhythmias, hypertension). Diabetes. Hyperthyroidism. Seizure disorders. Reevaluate periodically. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
During or within 2 weeks of MAOIs or tricyclics (increased cardiovascular effects); consider alternative therapy. Oral sympathomimetics: not recommended. Antagonized by β-blockers. Monitor digoxin. Caution with non-potassium sparing diuretics (eg, loop or thiazide); monitor.
Headache, tachycardia, pain, dizziness, pharyngitis, rhinitis; hypokalemia, paradoxical bronchospasm, cardiovascular effects, immediate hypersensitivity reactions (eg, rash, urticaria, angioedema).
Inhalation aerosol (w. dose counter)—8.5g (200 inh)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|